Cancer Biopsy Top Companies - Recent Developments, Business Strategy, Deal Strategy, Patent Strategy, Benchmarking and Management Outlook

Cancer Biopsy Market Size Analysis and Top Companies

The global cancer biopsy market size is estimated to hit around USD 145.02 billion by 2033 increasing from USD 25.90 billion in 2023, with a CAGR of 18.80% between 2023 and 2033. The top companies in the cancer biopsy are Myriad Genetics Inc., Guardant Health Inc., Exact Sciences Corporation, Bio-Rad Laboratories Inc., Agena Bioscience Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., ANGLE Plc., F. Hoffmann-La Roche Ltd., Myriad Genetics Inc.

Market Scope

Cancer Biopsy Market Companies

• Myriad Genetics Inc.
• Guardant Health Inc.
• Exact Sciences Corporation
• Bio-Rad Laboratories Inc.
• Agena Bioscience Inc.
• Personal Genome Diagnostics Inc.
• Exosome Diagnostics Inc.
• ANGLE Plc.
• F. Hoffmann-La Roche Ltd.

Recent Developments

• Guardant Health Inc. and MD Anderson established an agreement in January 2017 to make complete liquid biopsy a standard of care in cancer.
• Illumina Inc. reported in March 2021 that their NextSeq 550Dx platform and accompanying reagent kits had received medical device registration in Russia. Prior to this registration, the MiSeq Dx had already been approved as a medical device.

We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344